Kalydeco

Active Ingredient(s): Ivacaftor
FDA Approved: * January 31, 2012
Pharm Company: * VERTEX PHARMS
Category: Genetic Disorders

Ivacaftor is a medication used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis.[4][5] It is also included in combination medications, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor which are used to treat people with cystic fibrosis.[6][7&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Kalydeco 150 mg Oral Tablet
NDC: 51167-200
Labeler:
Vertex Pharmaceuticals Incorporated
Kalydeco 50 mg Oral Granule
NDC: 51167-300
Labeler:
Vertex Pharmaceuticals Incorporated
Kalydeco 75 mg Oral Granule
NDC: 51167-400
Labeler:
Vertex Pharmaceuticals Incorporated
Kalydeco 25 mg Oral Granule
NDC: 51167-600
Labeler:
Vertex Pharmaceuticals Incorporated